Press releaseGlobe Newswire
Apellis Pharmaceuticals
APLS · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- NewsVandana Singh
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
- Press releasePRNewswire
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
- News
Apellis Pharmaceuticals Q1 EPS $0.15 Beats $(0.36) Estimate, Sales $268.295M Beat $205.185M Estimate
- NewsSweta Killa
Tech Powers Nasdaq's Best Month Since 2020: These Stocks Are The Silent Performers
- Press releasePRNewswire
Are CCO, EHAB, APLS, VRE Obtaining Fair Deals for their Shareholders?
- Press releaseBusiness Wire
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
- Press releasePRNewswire
Are GSAT, APLS, FORA Obtaining Fair Deals for their Shareholders?
- Press releasePRNewswire
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
- Press releasePRNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS
- Press releasePRNewswire
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?
- NewsVandana Singh
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward
- NewsCaroline Ryan
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
- News
Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry
- Press releasePRNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
- Press releaseBusiness Wire
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook
- Press releasePRNewswire
Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
- Press releasePRNewswire
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?
- NewsVandana Singh
Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis Deal
- NewsAvi Kapoor
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
- NewsAvi Kapoor
Dow Jumps 400 Points; TD Synnex Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseBusiness Wire
APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
- Press releaseGlobe Newswire
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
- Press releaseGlobe Newswire
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
- Press releaseGlobe Newswire
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
- News
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
- Press releasePRNewswire
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
- NewsVandana Singh
Apellis Valuation Ignores Empaveli Potential, Says Analyst
- NewsPiero Cingari
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday?
- NewsPiero Cingari
Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday?
- News
Apellis Pharmaceuticals FY25 Preliminary U.S. Net Product Revenues Of $689M
- Press releaseGlobe Newswire
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
- NewsVandana Singh
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
- Press releaseGlobe Newswire
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.